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o Conflicts of Interest
eally Matter or Does No One
ead the Fine Print Anyway?
t is with interest that I read the expedited publication on the recently
nacted “black box” warnings on perflutren-containing ultrasound
ontrast agents in the December 18/25, 2007 issue of the Journal (1).
After reading the informative piece, which I believe enhanced
y understanding on the issue at hand, I glanced over the authors’
onflict-of-interest information near the bottom of the page (i.e.,
he fine print). I was surprised to find that 2 of the 3 authors are
aid consultants of Bristol-Myers Squibb Medical Imaging (who
anufactures Definity), and all 3 have some form of financial
nvolvement in the field of perflutren-containing ultrasound con-
rast agents. Although I have no issues with the decision to publish
his timely information, I cannot comprehend why an opinion
iece is solicited from authors who have direct financial relation-
hips with the companies manufacturing the products in question.
Does anyone read the conflict-of-interest fine print? And if not,
hat is its purpose? I believe stricter journal policies need to be
stablished for publication of opinion pieces that specifically focus on
crutinizing authors’ financial relationships with drug and device
anufacturers. How else is the average, unseasoned reader meant to
ppreciate the degree to which, if any, these authors’ comments have
een altered or encouraged by their conflicted interests?
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eply
e appreciate Dr. Vorobiof’s comments regarding our recent
aper (1). Although he found the paper “informative” and believes
t enhanced his understanding, he wishes it had been written by
uthors free of potential financial conflicts of interest.
Potential conflicts of interest are ubiquitous in medicine (and life).
ost clinical research involves collaboration between physicians and
ndustry, many National Institutes of Health-sponsored clinical trials
nclude industry support, and the majority of manuscript reviewers
onsidered “expert” on a particular topic also have potential conflicts.
o deal with this complex issue, the American College of Cardiology
oundation and the American Heart Association (2), the Heart
ditors Action Roundtable (3), and the Journal (4,5) all mandate full
isclosure of any potential financial conflicts of interest at the time of
anuscript submission, a policy with which we were compliant. To
ur knowledge, no one besides Dr. Vorobiof has suggested that
uthors with potential conflicts of interest be excluded from publish-
ng in medical journals. To do so would virtually abolish published
cientific reports, to the great detriment of medical science.
Finally, we want to correct the assertion that our manuscript was
olicited by the Journal. It was not. Additionally, no industry repre-
entative suggested, supported, or reviewed the manuscript. Our
rincipal “conflict of interest” is the safety and well being of patients,
o whom we are morally and professionally obligated to provide the
est care possible. If ultrasound contrast agents were unsafe for clinical
se, we would be the first to demand their removal from the market.
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